Skip to main content

Early value dossiers for medical technologies

The essential tool to understand the value proposition for your product and position it well with reimbursement/HTA stakeholders

Learn more
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

2026 DRG applications now accepted in Denmark

On August 6, 2024, the Danish Health Data Authority (Sundhedsdatastyrelsen) opened the application period for changes in the 2026 DRG logic. 

The applications should be developed using the application forms provided on the Danish Health Data Authority website and submitted via email (kliniskvalidering@sundhedsdata.dk). There are separate application forms to propose the change, removal, or addition of a new DRG.

The deadline for the submission of the applications is November 8, 2024.

See the full details in Danish here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.